Bhutan vs Bosnia and Herzegovina: The number of people with susceptibility test result for rifampicin
Bhutan
96.77
in 2021
Bosnia and Herzegovina
97.7
in 2021
Bhutan rank
40th
Bosnia and Herzegovina rank
38th
The number of people with susceptibility test result for rifampicin over time
- Bhutan
- Bosnia and Herzegovina
How they compare
Bosnia and Herzegovina currently reports 97.7 against 96.77 in Bhutan, a difference of 0.93.
The two have swapped places 3 times across 5 shared years of data; in 2017 it was Bhutan ahead.
Bhutan ranks 40th and Bosnia and Herzegovina ranks 38th of 146 countries.
Bhutan has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Bhutan | Bosnia and Herzegovina | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 93.89 | 93.68 | 0.2112 | Bhutan |
| 2020s | 98.38 | 97.68 | 0.7065 | Bhutan |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher the number of people with susceptibility test result for rifampicin, Bhutan or Bosnia and Herzegovina?
- Bosnia and Herzegovina, at 97.7 against 96.77 in Bhutan as of 2021.
- What is the difference in the number of people with susceptibility test result for rifampicin between Bhutan and Bosnia and Herzegovina?
- 0.93, with Bosnia and Herzegovina ahead.
- How many years of comparable data are there for Bhutan and Bosnia and Herzegovina?
- 5 years are reported by both, from 2017 to 2021.
- How do Bhutan and Bosnia and Herzegovina rank globally for the number of people with susceptibility test result for rifampicin?
- Bhutan ranks 40th and Bosnia and Herzegovina ranks 38th of 146 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.. Statizoid refreshes it automatically from the source and publishes the full history for both places.